Study of effectiveness and side effects of light therapy with oral medication called Khellin in Vitiligo patients.
Not Applicable
- Conditions
- Health Condition 1: L80- Vitiligo
- Registration Number
- CTRI/2020/02/023495
- Lead Sponsor
- Dr Lavin Bhatia
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients with stable lesions.
2.Patients between 18 and 60 years of age.
3.Patients who give informed consent for the study and photography.
4.Patients who can follow up in the opd
Exclusion Criteria
1.Patients who are unwilling to participate in the study.
2.Patients who had used any topical treatment 2 weeks and systemic treatment 4 weeks before starting on KUVA SOL.
3.Patients with history of photosensitive disorders, skin cancer, hepatic or renal disease and lesions over genitals.
4.Pregnant or lactating women.
5.Unstable vitiligo.
6.Patients with spontaneous repigmentation of depigmented macules.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.VASI ( Vitiligo Area Scoring Index) <br/ ><br>2.VIDA ( Vitiligo Disease Activity) <br/ ><br>3.VAS ( Visual Analogue Scale) <br/ ><br>4.Scoring by Dermosopy Image Processing Methodology. <br/ ><br>5. Side Effects. <br/ ><br>Timepoint: Every 4 weeks of initiating therapy for total of 16 weeks.
- Secondary Outcome Measures
Name Time Method 1. Liver function tests. <br/ ><br>2. Renal function tests. <br/ ><br>3. complete blood count. <br/ ><br>Timepoint: 0, 8 weeks, 16weeks.